Seed second close · Biotech
Laigo Bio adds €5.5m in second seed close
Biovance Capital and Kurma Partners bring the seed financing to €17m.
Laigo Bio announced a €5.5 million second seed close on March 23, 2026. New co-lead Biovance Capital contributed €4 million, while existing co-lead Kurma Partners added €1.5 million, taking the seed round to €17 million.
The Utrecht company will advance oncology and autoimmune programmes based on SureTACs, its platform for removing disease-driving proteins from cell surfaces.
Use of funds
Advance oncology programmes towards clinical development
Develop autoimmune, immunology and graft-rejection candidates